MA31881B1 - Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci - Google Patents

Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Info

Publication number
MA31881B1
MA31881B1 MA32636A MA32636A MA31881B1 MA 31881 B1 MA31881 B1 MA 31881B1 MA 32636 A MA32636 A MA 32636A MA 32636 A MA32636 A MA 32636A MA 31881 B1 MA31881 B1 MA 31881B1
Authority
MA
Morocco
Prior art keywords
methods
compositions
compounds
mek inhibitors
arylsifonamide
Prior art date
Application number
MA32636A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Barry Quart
Jeffrey N Miner
Stuart Dimock
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31881(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MA31881B1 publication Critical patent/MA31881B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)

Abstract

L'invention concerne des composés n-(arylamino)arylsulfonamide qui sont des inhibiteurs de mek comprenant des formes polymorphes cristallines présentant un profil de diffraction aux rayons x sur poudre spécifique et/ou un profil de calorimétrie à balayage différentiel spécifique. La présente invention concerne également des compositions pharmaceutiques comprenant les composés et des procédés d'utilisation des composés et des compositions décrits ici, y compris l'utilisation dans le traitement et/ou la prévention du cancer, de maladies hyperprolifératives et d'affections inflammatoires. L'invention concerne également des procédés de préparation des composés et des compositions décrits ici.
MA32636A 2007-07-30 2010-02-19 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci MA31881B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446608P 2008-03-06 2008-03-06
US3446408P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (fr) 2007-07-30 2008-07-28 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Publications (1)

Publication Number Publication Date
MA31881B1 true MA31881B1 (fr) 2010-12-01

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32636A MA31881B1 (fr) 2007-07-30 2010-02-19 Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Country Status (22)

Country Link
EP (1) EP2184984A4 (fr)
JP (3) JP2010535232A (fr)
KR (3) KR20150091434A (fr)
CN (2) CN103479604B (fr)
AP (1) AP2817A (fr)
AU (2) AU2008282338B2 (fr)
BR (1) BRPI0815659A2 (fr)
CA (1) CA2693390C (fr)
CO (1) CO6470808A2 (fr)
CR (1) CR11244A (fr)
DO (1) DOP2010000045A (fr)
EA (2) EA020624B1 (fr)
EC (1) ECSP109910A (fr)
HN (1) HN2010000203A (fr)
IL (1) IL203296A (fr)
MA (1) MA31881B1 (fr)
MX (1) MX2010001244A (fr)
NZ (1) NZ582929A (fr)
PH (1) PH12015501914A1 (fr)
SV (1) SV2010003469A (fr)
TN (1) TN2010000049A1 (fr)
WO (1) WO2009018233A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
CA3003213C (fr) * 2008-09-09 2021-07-20 F. Hoffmann-La Roche Ag Polymorphes de sulfonamides d'acyle
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
JP5767122B2 (ja) * 2009-03-11 2015-08-19 アルデア バイオサイエンシズ，インコーポレイティド 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
CN102666512B (zh) 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
EP2491015A1 (fr) * 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
CN103998935B (zh) * 2011-04-28 2018-10-16 索隆-基特林癌症研究协会 Hsp90组合疗法
PH12013502446A1 (en) * 2011-05-27 2014-01-20 Bayer Ip Gmbh Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
AU2013269809B2 (en) * 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
JO3754B1 (ar) * 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
AR099630A1 (es) * 2012-10-19 2016-08-10 Novartis Ag Preparación de un inhibidor de mek y formulación que lo comprende
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP2848246A1 (fr) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Compositions pharmaceutiques contenant du refametinib
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
EP3046557A1 (fr) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
AU2015306683B2 (en) 2014-08-25 2021-11-25 Societe Des Produits Nestle S.A. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN110799191B (zh) 2017-06-16 2023-05-26 贝塔制药有限公司 N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021067772A1 (fr) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Formulations d'inhibiteur d'axl
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
ATE218541T1 (de) * 1992-08-25 2002-06-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
AU2002330088B2 (en) * 2001-09-24 2009-09-03 Jessie L.-S. Au Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
AU2003251942A1 (en) * 2002-07-17 2004-02-02 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
EP1545553B1 (fr) * 2002-07-30 2011-07-13 Æterna Zentaris GmbH Utilisation d'alkylphosphocholines en association avec des medicaments antitumoraux
EP1871345B1 (fr) * 2005-04-12 2012-08-01 Elan Pharma International Limited Formules de nanoparticules d'erlotinib
CN101198582A (zh) * 2005-04-22 2008-06-11 橘生药品工业株式会社 4’－{2－[(1s,2r)－2－羟基－2－(4－羟基苯基)－1－甲基乙氨基]乙氧基}－3－异丙基－3’，5’－二甲基联苯羧酸盐酸盐的结晶多形
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
JP2015078199A (ja) 2015-04-23
EP2184984A1 (fr) 2010-05-19
CN103479604A (zh) 2014-01-01
EA201400552A1 (ru) 2014-09-30
KR20100092424A (ko) 2010-08-20
EA201000268A1 (ru) 2010-08-30
SV2010003469A (es) 2010-04-30
JP6309880B2 (ja) 2018-04-11
JP2010535232A (ja) 2010-11-18
KR20150091434A (ko) 2015-08-10
CA2693390C (fr) 2017-01-17
NZ582929A (en) 2012-03-30
CO6470808A2 (es) 2012-06-29
AU2008282338B2 (en) 2015-02-12
EP2184984A4 (fr) 2013-07-24
HN2010000203A (es) 2012-11-19
HK1147396A1 (en) 2011-08-12
PH12015501914A1 (en) 2017-07-31
BRPI0815659A2 (pt) 2014-09-30
CA2693390A1 (fr) 2009-02-05
CN103479604B (zh) 2016-08-10
AP2010005134A0 (en) 2010-02-28
EA032294B1 (ru) 2019-05-31
CN101808516A (zh) 2010-08-18
AU2008282338A1 (en) 2009-02-05
ECSP109910A (es) 2010-04-30
WO2009018233A1 (fr) 2009-02-05
CR11244A (es) 2010-05-20
TN2010000049A1 (en) 2011-09-26
JP2017125021A (ja) 2017-07-20
EA020624B1 (ru) 2014-12-30
AU2015200390B2 (en) 2017-02-23
KR20140098185A (ko) 2014-08-07
CN101808516B (zh) 2013-08-28
AP2817A (en) 2013-12-31
IL203296A (en) 2017-06-29
DOP2010000045A (es) 2010-10-31
MX2010001244A (es) 2010-08-31

Similar Documents

Publication Publication Date Title
MA31881B1 (fr) Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
TNSN08099A1 (fr) 1-h-imidazopyridines a substituant hydroxy et procedes
MA30967B1 (fr) Sels et formes cristallines de 2-methyl-2-methyl-2-[4-(3-methyl-2-oxo-8-quinolein-3-yl-2,3-dihydro-imidazo[4,5-c]quinolein-1-yl) - phenyl]-propionitrile.
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
WO2006099075A3 (fr) Amides substitues, procede pour les produire et procede pour les utiliser
WO2006053121A3 (fr) Certaines imidazo[1,2-a] pyrazin-8-ylamines et les procédés de fabrication et d'utilisation correspondants
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA33502B1 (fr) Composés pyrazolopyrimidine inhibiteurs des jak et procédés
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
WO2008033857A3 (fr) Amides substitués, procédé de production et d'utilisation desdits amides
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
TW200607807A (en) Macrocyclic beta-secretase inhibitors
UA86970C2 (en) Morpholine compounds
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
TW200738698A (en) Organic compounds
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci